Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Brain Neoplasms 12Glioblastoma 11Glioma 6Neoplasm Metastasis 4Carcinoma, Renal Cell 4Astrocytoma 4Oligodendroglioma 3Meningioma 3Gliosarcoma 3Paraganglioma 2Melanoma 2Kidney Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neurofibromatosis 1 1Neurofibromatoses 1Neoplasms 1Multiple Myeloma 1

Interventions

belzutifan 1Watchful Waiting 1Sunitinib 1Nivolumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangioblastoma × Sunitinib × CNS × Clear all
NCT00589784 2016-01-25

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
50 enrolled 6 charts
CNS

Brain Neoplasms, Meningioma, Neurofibromatosis 1, Neurofibromatosis 2, Central Nervous System Neoplasms, Neurofibromatoses, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡